Actions

::(-)-2β-(1,2,4-Oxadiazol-5-methyl)-3β-phenyltropane

::concepts

First::cocaine    Journal::category    -methyl-::pages    Potent::volume    Title::effects    Issue::''s''

{{#invoke:Infobox|infobox}}{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= ChemSpiderID= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey_comment= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= component1= component2= component3= component4= density= dependency_liability= drug_name= elimination_half-life= excretion= InChI= InChIKey= image2= imageL= imageR= imagename= image= legal_AU= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_EU= licence_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_US= pregnancy_AU_comment= pregnancy_US_comment= pregnancy_category= protein_bound= routes_of_administration= sec_combustion= SMILES= smiles= solubility= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Ni=No=Np=O=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru= S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=U=Uuo=Uup=Uus=Uut=V=W=Xe=Y=Yb=Zn=Zr |cat=Chemical articles with unknown parameter in Infobox drug |format=0|preview=1|errNS=0 }}

RTI-126 ((–)-2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane) is a phenyltropane derivative which acts as a potent monoamine reuptake inhibitor and stimulant drug. It is around 5 times more potent a stimulant than cocaine, but is relatively unselective. It binds to all three monoamine transporters, although still with some selectivity for the dopamine transporter.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> RTI-126 has a fast onset of effects and short duration of action, and its pharmacological profile in animals is among the closest to cocaine itself out of all the drugs in the RTI series. Its main application in scientific research has been in studies investigating the influence of pharmacokinetics on the abuse potential of stimulant drugs, with its rapid entry into the brain thought to be a key factor in producing its high propensity for development of dependence in animals.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>


The structurally related compound (–)-2β-(3-methyl-5-isoxazolyl)nortropane is a potent and selective agonist for nicotinic acetylcholine receptors, with twice the potency of nicotine.<ref>Cheng J, Izenwasser S, Zhang C, Zhang S, Wade D, Trudell ML. Synthesis and nicotinic acetylcholine receptor binding affinities of 2- and 3-isoxazolyl-8-azabicyclo[3.2.1]octanes. Bioorganic and Medicinal Chemistry Letters. April 2004; 14(7):1775-1778. doi:10.1016/j.bmcl.2004.01.025 PMID 15026069</ref>

(–)-2β-(3-methyl-5-isoxazolyl)nortropane

(-)-2β-(1,2,4-Oxadiazol-5-methyl)-3β-phenyltropane sections
Intro   See also   References  

PREVIOUS: IntroNEXT: See also
<<>>